# **Supplementary Information**

# Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: a mathematical modelling analysis

#### 1 Mathematical model

# 1.1 Description

We extended an age-structured deterministic SEIR compartmental model of SARS-CoV-2 transmission to capture the impact of different vaccination schedules. The main model captures the infection status of individuals as being in one of nine states (Figure S1):

- S = uninfected and therefore **susceptible** to infection
- E = **exposed** to infection but not yet infectious
- I<sub>MILD</sub> = **infected** and infectious with mild infection that does not require hospitalisation (this includes both symptomatic and asymptomatic infection)
- I<sub>CASE</sub> = **infected** and infectious with disease that will require hospitalisation
- IHOSP = cases that have been **hospitalised** in a general ward bed
- I<sub>ICU</sub> = cases that have been admitted to an intensive care unit (ICU)
- IREC = cases that have been stepped down from ICU into a general ward bed for recovery
- D = cases that have **died**
- R = infections and cases that have **recovered** and are immune to re-infection

Those that are susceptible become infected at a rate that depends on the level of infection in the community (i.e. the number of people in states  $I_{MILD}$  and  $I_{CASE}$ ), the transmission probability and an agestratified mixing matrix which captures the relative number of contacts that each age group has with their own age group and other age groups. This mixing matrix, along with the demography of the population, is obtained from studies that are representative of each of the four different World Bank income groups. Given the other model parameters, the transmission probability is varied to generate a different basic reproductive number,  $R_0$ . Following infection, cases proceed as shown by the arrows with the durations in each state and the probability of each pathway described below (see Tables S1 and S2). Following recovery, we allow individuals to lose naturally acquired immunity and therefore return to the susceptible state. Additional constraints are included in the hospitalisation pathway to capture situations in which the need exceeds capacity; with those that do not receive appropriate care experiencing higher death rates.

The process of vaccination is captured by mirroring the basic transmission model to also capture different states of vaccination (Figure S1):

- v<sub>0</sub> unvaccinated
- v<sub>1</sub> and v<sub>2</sub> vaccinated but not yet protected, reflecting the two-dose vaccine schedule and need to wait approximately 28 days from dose 1 for protection to develop
- v<sub>3</sub> and v<sub>4</sub> vaccinated and protected
- $v_5$  previously vaccinated but no longer protected, used to capture waning vaccine efficacy.

If the vaccine is not 100% efficacious, then in the protected states we assume there is partial efficacy. For example, if the vaccine is 90% efficacious then the risk of infection in states  $v_3$  and  $v_4$  is 90% lower than in state  $v_0$ ,  $v_1$ ,  $v_2$ , and  $v_5$ . We assume that vaccine efficacy is the same for susceptible and immune individuals. For those protected by both vaccine-derived and naturally acquired immunity, we assume that the most protective effect is dominant. For example, if natural immunity lasts for one year and vaccine-derived immunity for five years then the period of protection for a recently infected and now immune individual who receives the vaccine would be one year of full naturally acquired protection, followed by four years of vaccine-derived (leaky) protection.




Figure S1: Schematic of the SARS-CoV-2 transmission model. The schematic in the upper section is based on the model in Walker et al. Individuals in the susceptible (S), exposed (E) and recovered (R) compartments can be vaccinated. Vaccination status is stratified into 6 categories – those who are unvaccinated ( $v_0$ ), those who have recently been vaccinated but are not yet protected ( $v_1$  and  $v_2$ ) and those who are vaccinated and protected ( $v_3$  and  $v_4$ ) and those that have previously been vaccinated but are no longer protected ( $v_5$ ). Protection may refer to partial protection. We do not model revaccination of previously vaccinated individuals, due to all vaccination occurring within a one-month period. Pathways for receiving healthcare for the proportions of the population in the  $l_{HOSPITAL}$  and  $l_{ICU}$  compartments are described in Walker et al.  $l_1$ 

#### 1.2 Formal mathematical details

We stratify the population by age, a, and vaccination status, v. For the latter, we incorporate six categories – those who are unvaccinated  $(v_0)$ , those who have recently been vaccinated but are not yet protected  $(v_1$  and  $v_2)$  and those who are vaccinated and protected  $(v_3$  and  $v_4)$  and those who have previously been vaccinated but are no longer protected  $(v_5)$ . Note that we use the term "protected" here to denote partial protection because we model a leaky vaccine rather than sterile immunity.

Vaccines are targeted by age groups at a rate  $\kappa(a)$ . To specify prioritisation strategies, we define a vector of current vaccine coverage  $C_a$  by age group (a) and a matrix of coverage targets  $T_{sa}$  where rows (s) represent ordered prioritisation steps and columns (a) the age group. For a given prioritisation step, e.g. s=1, vaccination, up to a maximum specified rate expressed as the total number of vaccinees per day, is provided to all age groups that satisfy  $C_a < T_{1a}$ . Vaccinations are distributed to target age groups in proportion to the size of the unvaccinated populations. When all target coverages in the current prioritisation step are met, the step (s) is incremented (+1) and the process repeated. When all coverage targets in the final prioritisation step are met, vaccination is ceased. We assume that individuals may only be vaccinated once. Protection is provided either against infection – reducing the transmission parameter  $\beta$  by a constant factor  $1-v_{inf}(a)$ ; against severe disease – reducing the rate of hospitalisation  $\phi(a)$  by a constant factor  $1-v_{dis}(a)$ ; or against infection, with additional protection against severe disease in vaccinated individuals who experience breakthrough infection (combined modes of efficacy).

The transmission model within each vaccine category is identical to that described in Walker et al.<sup>1</sup> with the inclusion of reversion of natural immunity which is modelled by an additional flow from the recovered compartment back to the susceptible compartment (Figure S1). Let S(t,a,v) denote the susceptible population in age group a with vaccination status v at time t,  $E_1(t,a,v)$  and  $E_2(t,a,v)$  two sequential latent periods,  $I_{MILD}(t,a,v)$  infections that are either asymptomatic or symptomatic but do not require hospitalisation,  $I_{CASE,0}(t,a,v)$  and  $I_{CASE,1}(t,a,v)$  two sequential states for infections that are symptomatic and will subsequently require hospitalisation.  $I_{HOSPITAL,1}(t,a,v)$  and  $I_{HOSPITAL,1}(t,a,v)$  are two sequential states for infections requiring a general hospital bed.  $I_{ICU,0}(t,a,v)$  and  $I_{ICU,1}(t,a,v)$  are two sequential states for infections requiring an ICU bed.  $I_{REC,0}(t,a,v)$  and  $I_{REC,1}(t,a,v)$  are two sequential states for hospitalised infections in general beds recovering from ICU whilst  $R_1(t,a,v)$  and  $R_2(t,a,v)$  are two sequential compartments capturing those that have recovered and are currently immune to reinfection, and D(t,a,v,) are those that have died from the disease in age group a and with vaccination status v. We further split  $I_{HOSPITAL,i}(t,a,v)$  and  $I_{ICU,i}(t,a,v)$  into states i=1,2 to track those that either receive or do not receive their hospital or ICU bed respectively (1, 0 respectively depending on capacity constraints) and through these route either die or recover (0 and 1 respectively) in order to capture different durations of stay in hospital dependent on outcome. For example, the state tracking those that require a general bed, receive it and go on to die is  $I_{HOSPITAL,i}(t,a,v,1,0)$  whilst the state tracking those that require a general bed, do not receive it and go on to die is  $I_{HOSPITAL,i}(t,\alpha,v,0,0)$ . In the equations below we use the Kronecker Delta function  $\delta(\cdot)$  to capture capacity constraints with this equal to 1 if there is capacity (Hospital or ICU) and zero otherwise. Contacts between age-classes are captured using the social contact mixing matrix where c(a, a') denotes the rate of contacts between individuals in age groups a and a'. Age-dependent severity of disease is captured with an agedependent mortality rate  $\mu(a)$ . Note that hospitalised individuals and those in ICU do not contribute to the force of infection.

Given that our focus is on short-term dynamics we do not model births, deaths, or aging. The group of individuals therefore represents their age in 2020. The equations for each of the six vaccination groups are given in Section 1.3. The parameter symbols, description and values are shown in Tables S1 and S2.

A mean duration in ICU of 13.3 days is reported from a study of clinical outcomes of COVID-19 hospitalised patients across 42 countries<sup>2</sup>. In UK data, 60.1% of those entering ICU survive with the ratio of the duration of time spent in ICU in those that die to those who survive reported as 0.75<sup>3</sup>. We use these two additional pieces of information to obtain the mean duration of stay in ICU for individuals who die and those who survive.

The model incorporates three age-dependent parameters – the probability of hospitalisation given infection  $\phi_1(a)$ ; the probability of requiring ICU given hospitalisation  $\phi_2(a)$ ; and the probability of dying  $\mu(a)$  given hospitalisation (when hospital capacity is not saturated, we make the simplifying assumption that all deaths occur in hospital) (Table S2). The probability of dying given hospitalisation is obtained from estimates of the infection fatality ratio from a recent systematic review and model-based analysis of the literature<sup>4</sup>. Deaths in hospital occur from both those entering ICU and those in general beds, with the proportion in each determined by an age-dependent parameter (Table S2). The shape of this distribution reflects a lower proportion of elderly patients being admitted to ICU and is informed by unpublished UK data. For a UK demography, this parameterisation results in 20% of all hospitalised cases requiring ICU (consistent with the ISARIC international study reporting  $18\%^2$ ), a case fatality ratio in ICU of 48% (compared with the ISARIC international study reporting  $54\%^2$ ) and 41% of deaths occurring in ICU (slightly higher than the ISARIC international study reporting  $36\%^2$ ).

The IFR estimates presented in Brazeau *et al.*<sup>4</sup> also include a breakdown in five-year age bands for those above 80 years of age. To obtain the correct IFR in the 80+ age group we weighted the IFR reported by 5-year age bands by the proportion of the 80+ population in each 5-year band for each income setting to obtain an average IFR in the 80+ age group.

Table S1: Parameter descriptions and values.

Parameter	Symbol	Value	Description
<b>Epidemiological Parameters</b>			
Transmission parameter	β	-	Calculated from R <sub>0</sub> (See Table 1)
Mean latent period	1	4.6 days	Estimated at 5.1 days <sup>5–7</sup> . The last 0.5 days are
	α		incorporated in the infectious periods to capture pre-
			symptomatic infectivity
Mean duration of mild infection	$\frac{1}{\gamma_1}$	2.1 days	Incorporates 0.5 days of infectiousness prior to
	$\gamma_1$		symptoms. In combination with mean duration of
			severe illness this gives a mean serial interval of 6.75
			days <sup>8</sup> .
Mean duration of severe	1	4.5 days	Mean onset-to-admission of 4 days <sup>9</sup> . Values in the wider
infection prior to hospitalisation	$\overline{\gamma_2}$		literature range from 1.2 days to 12 days <sup>5–7,10,11</sup> .
			Includes 0.5 days of infectiousness prior to symptom
			onset.
Mean duration of hospitalisation	1	9 days	Median of values identified in <sup>10–14</sup> .
for non-critical cases if survive	$\overline{\gamma_{3,1}}$		
Mean duration of hospitalisation	1	9 days	Median of values identified in <sup>10–14</sup> .
for non-critical cases if die	$\overline{\gamma_{3,0}}$		
Mean duration in ICU if survive	1	14.8 days	Mean duration in ICU of 13.3 days from a study across
	$\overline{\gamma_{4,1}}$		42 countries <sup>2</sup> . Ratio of duration in critical care if die:
			duration in critical care if survive of 0.75 and 60.1%
			probability of survival in ICU <sup>3</sup> .
Mean duration in ICU if die	1	11.1 days	Mean duration in ICU of 13.3 days from a study across
	$\overline{\gamma_{4,0}}$		42 countries <sup>2</sup> . Ratio of duration in critical care if die:
			duration in critical care if survive of 0.75 and 60.1%
			probability of survival in ICU <sup>3</sup> .
Mean duration in recovery after	1	3.0 days	Working assumption
ICU	$\gamma_5$		
Infection fatality ratio (IFR)	μ(a)	-	Age-dependent <sup>4</sup> (see below)
Hospitalisation proportion	$\phi_1(a)$	-	Age-dependent <sup>15</sup> (see below)
Proportion of hospitalisations	$\phi_2(a)$	-	Age-dependent <sup>15</sup> (see below)
requiring ICU			
Mean duration of naturally	1/ρ	365 days (default), infinite, or	16–20
acquired immunity		183 days	
Vaccination Parameters		l	
Age-dependent rate of	κ(a)	-	Age-dependent assumption: set such that number of
vaccination			people vaccinated per day in each age group achieves
			target coverage by the end of the vaccination period
Mean time to develop vaccine-	1/ω	7 days	21–25
acquired immunity following			
second dose			
Mean duration of vaccine-	$1/\psi$	5000 days (default), 365 days	26
acquired immunity		or 183 days	
Efficacy against infection	1	-	Age-dependent (see Table S3) <sup>27–32</sup>
. <del>.</del>	$-v_{inf}(a)$		
Efficacy against disease	1	-	Age-dependent (see Table S3) <sup>28,30,33–36</sup>
, -	$-v_{dis}(a)$		
Dose schedule	-	2 doses (default); 1 dose	27,30–32

Table S2: Age-dependent parameters for hospitalisation and death.

Age group	Proportion of	Proportion of	Proportion of	Proportion of	Proportion of	Infection
	infections	hospitalised	hospital	non-ICU cases	ICU cases	fatality ratio
	hospitalised15	cases	deaths	dying	dying	(IFR) <sup>4</sup>
		requiring	occurring in			
		ICU <sup>15</sup>	ICU			
0 to 4	0.001	0.181	0.8	0.013	0.227	0.00004
5 to 9	0.001	0.181	0.8	0.014	0.252	0.00007
10 to 14	0.002	0.181	0.8	0.016	0.281	0.00011
15 to 19	0.002	0.137	0.8	0.016	0.413	0.00017
20 to 24	0.003	0.122	0.8	0.018	0.518	0.00026
25 to 29	0.005	0.123	0.8	0.020	0.573	0.00041
30 to 34	0.007	0.136	0.8	0.023	0.576	0.00064
35 to 39	0.009	0.161	0.8	0.026	0.543	0.00100
40 to 44	0.013	0.197	0.8	0.030	0.494	0.00156
45 to 49	0.018	0.242	0.8	0.036	0.447	0.00245
50 to 54	0.025	0.289	0.8	0.042	0.417	0.00384
55 to 59	0.036	0.327	0.8	0.050	0.411	0.00601
60 to 64	0.050	0.337	0.8	0.056	0.443	0.00941
65 to 69	0.071	0.309	0.8	0.060	0.539	0.01473
70 to 74	0.100	0.244	0.6	0.123	0.570	0.02307
75 to 79	0.140	0.160	0.4	0.184	0.643	0.03613
80+	0.233	0.057	0.15	0.341	0.993	_*
80 to 84	-	-	-	-	-	0.05659
85 to 89	-	-	-	=	-	0.08862
90+	-	-	-	-	-	0.17370

<sup>\*</sup> To standardise input age groups for modelling, IFRs in 80 to 85, 85 to 90 and 90+ age groups are aggregated to the 80+ age group using country-specific demography.

Table S3: Scenarios for modes of vaccine efficacy.

Mode of efficacy scenario	Efficacy against infection	Efficacy against disease
Combined (default)	90%	Additional 60% efficacy for
		breakthrough infections
Infection only	90%	No additional protection
Disease only	0%	90%
Combined, with	90%; 45% in 65+ year age group	Additional 60% efficacy for
immunosenescence		breakthrough infections
Combined, lower efficacy	70%	Additional 60% efficacy for
		breakthrough infections

# 1.3 Mathematical model equations

#### 1.3.1 Vaccination group v<sub>0</sub> - unvaccinated

$$\begin{split} & \frac{dS(t,a,v_0)}{dt} = 2\rho R_2(t,a,v_0) - \beta \frac{S(t,a,v_0)}{N} \sum_{a'} c(a,a') | \sum_{v} (I_{MILD}(t,a',v) + I_{CASE}(t,a',v)) | -\kappa(a)S(t,a,v_0) \\ & \frac{dE_1(t,a,v_0)}{dt} = \beta \frac{S(t,a,v_0)}{N} \sum_{a'} c(a,a') | \sum_{v} (I_{MILD}(t,a',v) + I_{CASE}(t,a',v)) | -2\alpha E_1(t,a,v_0) - \kappa(a)E_1(t,a,v_0) \\ & \frac{dE_1(t,a,v_0)}{dt} = 2aE_1(t,a,v_0) - 2aE_2(t,a,v_0) - \kappa(a)E_2(t,a,v_0) \\ & \frac{dI_{MIDD}(t,a,v_0)}{dt} = (1 - \phi_1(a))(2aE_2(t,a,v_0)) - \gamma_1I_{MILD}(t,a,v_0) \\ & \frac{dI_{CASE,0}(t,a,v_0)}{dt} = \phi_1(a)(2aE_2(t,a,v_0)) - \gamma_2I_{CASE,0}(t,a,v_0) \\ & \frac{dI_{CASE,0}(t,a,v_0)}{dt} = 2\gamma_2I_{CASE,0}(t,a,v_0) - 2\gamma_2I_{CASE,0}(t,a,v_0) \\ & \frac{dI_{CASE,0}(t,a,v_0)}{dt} = (1 - \delta(H))\mu(a)(1 - \phi_2(a))2\gamma_2I_{CASE,1}(t,a,v_0) - 2\gamma_2a^I_{MOSPITAL,0}(t,a,v_0,0) \\ & \frac{dI_{MOSPITAL,0}(t,a,v_0,0,0)}{dt} = (1 - \delta(H))\mu(a)(1 - \phi_2(a))2\gamma_2I_{CASE,1}(t,a,v_0) - 2\gamma_2a^I_{MOSPITAL,0}(t,a,v_0,1,0) \\ & \frac{dI_{MOSPITAL,1}(t,a,v_0,1,0)}{dt} = \frac{\partial (H)(\mu(a)(1 - \phi_2(a))2\gamma_2I_{CASE,1}(t,a,v_0) - 2\gamma_2a^I_{MOSPITAL,0}(t,a,v_0,1,0) \\ & \frac{dI_{MOSPITAL,1}(t,a,v_0,1,0)}{dt} = 2\gamma_3A^I_{MOSPITAL,0}(t,a,v_0,1,0) - 2\gamma_3A^I_{MOSPITAL,1}(t,a,v_0,0,0) \\ & \frac{dI_{MOSPITAL,1}(t,a,v_0,1,0)}{dt} = 2\gamma_3A^I_{MOSPITAL,0}(t,a,v_0,1,0) - 2\gamma_3A^I_{MOSPITAL,1}(t,a,v_0,0,0) \\ & \frac{dI_{MOSPITAL,1}(t,a,v_0,0,0)}{dt} = 2\gamma_3A^I_{MOSPITAL,0}(t,a,v_0,0,0) - 2\gamma_3A^I_{MOSPITAL,1}(t,a,v_0,0,0) \\ & \frac{dI_{MOSPITAL,1}(t,a,v_0,0,0)}{dt} = 2\gamma_3A^I_{MOSPITAL,0}(t,a,v_0,0,0) - 2\gamma_3A^I_{MOSPITAL,1}(t,a,v_0,0,0) \\ & \frac{dI_{MOSPITAL,0}(t,a,v_0,0,0)}{dt} = 2\gamma_3A^I_{MOSPITAL,0}(t,a,v_0,0,0) - 2\gamma_3A^I_{MOSPITAL,0}(t,a,v_0,0,0) \\ & \frac{dI_{MOSPITAL,0}(t,a,v_0,0,0)}{dt} = 2\gamma_3A^I_{MOSPITAL,0}(t,a,v_0,0,0) - 2\gamma_3A^I_{MOSPITAL,0}(t,a,v_0,0,0) \\ & \frac{dI_{MOSPITAL,0}(t,a,v_0,0,0)}{dt} = 2\gamma_3A^I_$$

# 1.3.2 Vaccination group v<sub>1</sub> - vaccinated but not yet protected (state 1)

$$\frac{dS(t,a,v_1)}{dt} = \kappa(a)S(t,a,v_0) + 2\rho R_2(t,a,v_1) - \beta \frac{S(t,a,v_1)}{N} \sum_{a'} c(a,a') \sum_{v} (I_{MID}(t,a',v) + I_{cASF}(t,a',v)) + I_{cASF}(t,a,v_1)$$

$$-2\omega S(t,a,v_1) \\ -2\omega S(t,a,v_1) \\ -2\omega E_1(t,a,v_1) \\ -2\omega E_1(t,a,v_1) \\ -2\omega E_1(t,a,v_1) \\ -2\omega E_1(t,a,v_1) \\ -2\omega E_2(t,a,v_1) \\ -2\omega E_2(t$$

$$\begin{split} \frac{dR_1(t,a,v_1)}{dt} &= \kappa(a)R_1(t,a,v_0) + \gamma_1 I_{MILD}(t,a,v_1) + 2\gamma_{3,1} I_{HOSPITAL,1}(t,a,v_1,0,1) + 2\gamma_{3,1} I_{HOSPITAL,1}(t,a,v_1,1,1) \\ &\quad + 2\gamma_5 I_{REC,1}(t,a,v_1) + 2\gamma_{4,1} I_{ICU,1}(t,a,v_1,0,1) + 2\gamma_{4,1} I_{ICU,1}(t,a,v_1,1,1) - 2\rho R_1(t,a,v_1) \\ &\quad - 2\omega R(t,a,v_1) \\ \frac{dR_2(t,a,v_1)}{dt} &= \kappa(a)R_2(t,a,v_0) + 2\rho R_1(t,a,v_1) - 2\rho R_2(t,a,v_1) \\ \frac{dD(t,a,v_1)}{dt} &= 2\gamma_{3,0} I_{HOSPITAL,1}(t,a,v_1,0,0) + 2\gamma_{3,0} I_{HOSPITAL,1}(t,a,v_1,1,0) + 2\gamma_{4,0} I_{ICU,1}(t,a,v_1,0,0) \\ &\quad + 2\gamma_{4,0} I_{ICU,1}(t,a,v_1,1,0) \end{split}$$

#### 1.3.3 Vaccination group v<sub>2</sub> - vaccinated but not yet protected (state 2)

$$\begin{split} &\frac{dS(t,a,v_2)}{dt} = 2\rho R_2(t,a,v_2) - \beta \frac{S(t,a,v_2)}{N} \sum_{a} c(a,a') [\sum_{v} (l_{MILD}(t,a',v) + l_{CASE}(t,a',v))] + 2\omega S(t,a,v_1) \\ &- 2\omega S(t,a,v_2) \\ &\frac{dE_1(t,a,v_2)}{dt} = \beta \frac{S(t,a,v_2)}{N} \sum_{a} c(a,a') [\sum_{v} (l_{MILD}(t,a',v) + l_{CASE}(t,a',v))] - 2aE_1(t,a,v_2) + 2\omega E_1(t,a,v_1) \\ &- 2\omega E_1(t,a,v_2) \\ &- 2\omega E_1(t,a,v_2) \\ &= 2aE_1(t,a,v_2) - 2aE_2(t,a,v_2) + 2\omega E_2(t,a,v_1) - 2\omega E_2(t,a,v_2) \\ &\frac{dE_2(t,a,v_2)}{dt} = 2aE_1(t,a,v_2) - 2aE_2(t,a,v_2) + 2\omega E_2(t,a,v_1) - 2\omega E_2(t,a,v_2) \\ &\frac{dE_{MIND}(t,a,v_2)}{dt} = (1 - \phi_1(a))(2aE_2(t,a,v_2)) - \gamma_1 l_{MILD}(t,a,v_2) + 2\omega l_{MILD}(t,a,v_1) - 2\omega l_{MILD}(t,a,v_2) \\ &\frac{dI_{CASE,0}(t,a,v_2)}{dt} = q_1(a)(2aE_2(t,a,v_2)) - 2\gamma_2 l_{CASE,0}(t,a,v_2) + 2\omega l_{CASE,0}(t,a,v_1) - 2\omega l_{CASE,0}(t,a,v_2) \\ &\frac{dI_{CASE,1}(t,a,v_2)}{dt} = 2\gamma_2 l_{CASE,0}(t,a,v_2) - 2\gamma_2 l_{CASE,1}(t,a,v_2) + 2\omega l_{CASE,1}(t,a,v_1) - 2\omega l_{CASE,1}(t,a,v_2) \\ &\frac{dI_{CASE,1}(t,a,v_2)}{dt} = (1 - \delta(H))\mu(a)(1 - \phi_2(a))2\gamma_2 l_{CASE,1}(t,a,v_2) - 2\gamma_3 d_{HOSPITAL,0}(t,a,v_2,0.0) \\ &\frac{dI_{DOSPITAL,0}(t,a,v_2,0.0)}{dt} = (1 - \delta(H))\mu(a)(1 - \phi_2(a))2\gamma_2 l_{CASE,1}(t,a,v_2) - 2\gamma_3 d_{HOSPITAL,0}(t,a,v_2,0.0) \\ &\frac{dI_{DOSPITAL,1}(t,a,v_2,0.0)}{dt} = 2\gamma_3 d_{HOSPITAL,1}(t,a,v_2,0.0) - 2\gamma_3 d_{HOSPITAL,1}(t,a,v_2,0.0) \\ &\frac{dI_{DOSPITAL,0}(t,a,v_2,0.0)}{dt} = \delta(H)\mu(a)(1 - \phi_2(a))2\gamma_2 l_{CASE,1}(t,a,v_2) - 2\gamma_3 d_{HOSPITAL,0}(t,a,v_2,1.0) \\ &\frac{dI_{DOSPITAL,0}(t,a,v_2,1.0)}{dt} = \delta(H)\mu(a)(1 - \phi_2(a))2\gamma_2 l_{CASE,1}(t,a,v_2) - 2\gamma_3 d_{HOSPITAL,0}(t,a,v_2,1.0) \\ &\frac{dI_{HOSPITAL,0}(t,a,v_2,1.0)}{dt} = 2\gamma_3 d_{HOSPITAL,0}(t,a,v_2,1.0) - 2\omega d_{HOSPITAL,0}(t,a,v_2,1.0) \\ &\frac{dI_{HOSPITAL,0}(t,a,v_2,1.0)}{dt} = 2\gamma_3 d_{HOSPITAL,0}(t,a,v_2,1.0) - 2\gamma_3 d_{HOSPITAL,0}(t,a,v_2,1.0) + 2\omega d_{HOSPITAL,1}(t,a,v_2,0.1) \\ &\frac{dI_{HOSPITAL,0}(t,a,v_2,0.1)}{dt} = 2\gamma_3 d_{HOSPITAL,0}(t,a,v_2,0.1) - 2\gamma_3 d_{HOSPITAL,1}(t,a,v_2,0.1) + 2\omega d_{HOSPITAL,1}(t,a,v_2,0.1) \\ &\frac{dI_{HOSPITAL,0}(t,a,v_2,0.0)}{dt} = 2\gamma_3 d_{HOSPITAL,0}(t,a,v_2,0.1) - 2\gamma_3 d_{HOSPITAL,1}(t,a,v_2,0.1) + 2\omega d_{HOSPITAL,1}(t,a,v_2,0.0) \\ &\frac{dI_{HO$$

$$\begin{split} \frac{dI_{ICU,1}(t,a,v_2,1,0)}{dt} &= 2\gamma_{4,0}I_{ICU,0}(t,a,v_2,1,0) - 2\gamma_{4,0}I_{ICU,1}(t,a,v_2,1,0) + 2\omega I_{ICU,1}(t,a,v_1,1,0) - 2\omega I_{ICU,1}(t,a,v_2,1,0) \\ \frac{dI_{ICU,0}(t,a,v_2,0,1)}{dt} &= (1 - \delta(ICU))(1 - \mu(a))\phi_2(a)2\gamma_2I_{CASE,1}(t,v_2,a) - 2\gamma_{4,1}I_{ICU,0}(t,a,v_2,0,1) \\ &+ 2\omega I_{ICU,0}(t,a,v_1,0,1) - 2\omega I_{ICU,0}(t,a,v_2,0,1) \\ \frac{dI_{ICU,1}(t,a,v_2,0,1)}{dt} &= 2\gamma_{4,1}I_{ICU,0}(t,a,v_2,0,1) - 2\gamma_{4,1}I_{ICU,1}(t,a,v_2,0,1) + 2\omega I_{ICU,1}(t,a,v_1,0,1) - 2\omega I_{ICU,1}(t,a,v_2,0,1) \\ \frac{dI_{ICU,0}(t,a,v_2,1,1)}{dt} &= \delta(ICU)(1 - \mu(a))\phi_2(a)2\gamma_2I_{CASE,1}(t,a,v_2) - 2\gamma_{4,1}I_{ICU,0}(t,a,v_2,1,1) + 2\omega I_{ICU,0}(t,a,v_1,1,1) \\ &- 2\omega I_{ICU,0}(t,a,v_2,1,1) \\ \frac{dI_{ICU,1}(t,a,v_2,1,1)}{dt} &= 2\gamma_{4,1}I_{ICU,0}(t,a,v_2,1,1) - 2\gamma_{4,1}I_{ICU,1}(t,a,v_2,1,1) + 2\omega I_{ICU,1}(t,a,v_1,1,1) - 2\omega I_{ICU,1}(t,a,v_2,1,1) \\ \frac{dI_{REC,0}(t,a,v_2)}{dt} &= 2\gamma_{4,1}I_{ICU,1}(t,a,v_2,0,1) + 2\gamma_{4,1}I_{ICU,1}(t,a,v_2,1,1) - 2\gamma_{5}I_{REC,0}(t,a,v_2) + 2\omega I_{REC,0}(t,a,v_1) \\ &- 2\omega I_{REC,0}(t,a,v_2) \\ \frac{dI_{REC,1}(t,a,v_2)}{dt} &= 2\gamma_{5}I_{REC,0}(t,a,v_2) - 2\gamma_{5}I_{REC,1}(t,a,v_2) + 2\omega I_{REC,1}(t,a,v_1) - 2\omega I_{REC,1}(t,a,v_2) \\ \frac{dI_{REC,1}(t,a,v_2)}{dt} &= \gamma_{1}I_{MILD}(t,a,v_2) + 2\gamma_{3,1}I_{HOSPITAL,1}(t,a,v_2,0,1) + 2\gamma_{3,1}I_{HOSPITAL,1}(t,a,v_2,1,1) + 2\gamma_{5}I_{REC,1}(t,a,v_1) \\ &- 2\omega R_1(t,a,v_2) \\ \frac{dR_2(t,a,v_2)}{dt} &= 2\rho R_1(t,a,v_2) - 2\rho R_2(t,a,v_2) + 2\omega R_2(t,a,v_1) - 2\omega R_2(t,a,v_2) \\ \frac{dR_2(t,a,v_2)}{dt} &= 2\gamma_{4,1}I_{ROSPITAL,1}(t,a,v_2,0,0) + 2\gamma_{4,1}I_{ROSPITAL,1}(t,a,v_2,1,0) + 2\gamma_{4,1}I_{ROSPITAL,1}(t,a,v_2,0,0) \\ &+ 2\gamma_{4,0}I_{ROSPITAL,1}(t,a,v_2,0,0) + 2\gamma_{3,0}I_{HOSPITAL,1}(t,a,v_2,1,0) + 2\gamma_{4,0}I_{ROSPITAL,1}(t,a,v_2,0,0) \\ &+ 2\gamma_{4,0}I_{ROSPITAL,1}(t,a,v_2,1,0) \end{pmatrix}$$

#### 1.3.4 Vaccination group v<sub>3</sub> - vaccinated and protected (state 1)

$$\frac{dS(t, a, v_3)}{dt} = 2\rho R_2(t, a, v_3) - v_{inf}(a) \frac{S(t, a, v_3)}{N} \sum_{a'} c(a, a') \left[ \sum_{v} \left( l_{MILD}(t, a', v) + l_{CASE}(t, a', v) \right) \right] + 2\omega S(t, a, v_2) \\ - 2\psi S(t, a, v_3) \\ - 2\psi S(t, a, v_3) \\ - 2\psi S(t, a, v_3) = v_{inf}(a) \frac{S(t, a, v_3)}{N} \sum_{a'} c(a, a') \left[ \sum_{v} \left( l_{MILD}(t, a', v) + l_{CASE}(t, a', v) \right) \right] - 2\alpha E_1(t, a, v_2) + 2\omega E_1(t, a, v_2) \\ - 2\psi E_1(t, a, v_3) \\ - 2\psi E_1(t, a, v_3) - 2\alpha E_2(t, a, v_3) + 2\omega E_2(t, a, v_2) - 2\psi E_2(t, a, v_3) \\ \frac{dE_2(t, a, v_3)}{dt} = 2\alpha E_1(t, a, v_3) - 2\alpha E_2(t, a, v_3) + 2\omega E_2(t, a, v_2) - 2\psi E_2(t, a, v_3) \\ \frac{dE_{10SE}(t, a, v_3)}{dt} = v_{old}(a)\phi_1(a)(2\alpha E_2(t, a, v_3)) - y_1 l_{MID}(t, a, v_3) + 2\omega l_{CASE}(t, a, v_2) - 2\psi l_{CASE}(t, a, v_3) \\ \frac{dE_{10SE}(t, a, v_3)}{dt} = v_{old}(a)\phi_1(a)(2\alpha E_2(t, a, v_3)) - 2y_2 l_{CASE}(t, a, v_3) + 2\omega l_{CASE}(t, a, v_2) - 2\psi l_{CASE}(t, a, v_3) \\ \frac{dE_{10SE}(t, a, v_3)}{dt} = v_{old}(a)\phi_1(a)(2\alpha E_2(t, a, v_3)) - 2y_2 l_{CASE}(t, a, v_3) + 2\omega l_{CASE}(t, a, v_2) - 2\psi l_{CASE}(t, a, v_3) \\ \frac{dE_{10SE}(t, a, v_3)}{dt} = v_{old}(a)\phi_1(a)(2\alpha E_2(t, a, v_3)) - 2y_2 l_{CASE}(t, a, v_3) + 2\omega l_{CASE}(t, a, v_2) - 2\psi l_{CASE}(t, a, v_3) \\ \frac{dH_{10SE}(t, a, v_3)}{dt} = v_{old}(a)\phi_1(a)(1 - \phi_2(a))2y_2 l_{CASE}(t, a, v_3) - 2y_{AiloSE}(t, a, v_3) - 2\psi l_{CASE}(t, a, v_3) \\ \frac{dH_{10SE}(t, a, v_3)}{dt} = v_{old}(a)v_{old}(t, a, v_3) - v_{old}(t, a, v_3) \\ \frac{dH_{10SE}(t, a, v_3)}{dt} = v_{old}(t, a, v_3) \\ \frac{d$$

$$\begin{split} \frac{dI_{ICU,1}(t,a,v_3,1,0)}{dt} &= 2\gamma_{4,0}I_{ICU,0}(t,a,v_3,1,0) - 2\gamma_{4,0}I_{ICU,1}(t,a,v_3,1,0) + 2\omega I_{ICU,1}(t,a,v_2,1,0) - 2\psi I_{ICU,1}(t,a,v_3,1,0) \\ \frac{dI_{ICU,0}(t,a,v_3,0,1)}{dt} &= (1 - \delta(ICU))(1 - \mu(a))\phi_2(a)2\gamma_2I_{CASE,1}(t,v_3,a) - 2\gamma_{4,1}I_{ICU,0}(t,a,v_3,0,1) \\ &+ 2\omega I_{ICU,0}(t,a,v_2,0,1) - 2\psi I_{ICU,0}(t,a,v_3,0,1) \\ \frac{dI_{ICU,1}(t,a,v_3,0,1)}{dt} &= 2\gamma_{4,1}I_{ICU,0}(t,a,v_3,0,1) - 2\gamma_{4,1}I_{ICU,1}(t,a,v_3,0,1) + 2\omega I_{ICU,1}(t,a,v_2,0,1) - 2\psi I_{ICU,1}(t,a,v_3,0,1) \\ \frac{dI_{ICU,0}(t,a,v_3,1,1)}{dt} &= \delta(ICU)(1 - \mu(a))\phi_2(a)2\gamma_2I_{CASE,1}(t,a,v_3) - 2\gamma_{4,1}I_{ICU,0}(t,a,v_3,1,1) + 2\omega I_{ICU,0}(t,a,v_2,1,1) \\ &- 2\psi I_{ICU,0}(t,a,v_3,1,1) \\ \frac{dI_{ICU,1}(t,a,v_3,1,1)}{dt} &= 2\gamma_{4,1}I_{ICU,0}(t,a,v_3,1,1) - 2\gamma_{4,1}I_{ICU,1}(t,a,v_3,1,1) + 2\omega I_{ICU,1}(t,a,v_2,1,1) - 2\psi I_{ICU,1}(t,a,v_3,1,1) \\ \frac{dI_{REC,0}(t,a,v_3)}{dt} &= 2\gamma_{4,1}I_{ICU,1}(t,a,v_3,0,1) + 2\gamma_{4,1}I_{ICU,1}(t,a,v_3,1,1) - 2\gamma_{5}I_{REC,0}(t,a,v_3) + 2\omega I_{REC,0}(t,a,v_2) \\ &- 2\psi I_{REC,0}(t,a,v_3) \\ \frac{dI_{REC,1}(t,a,v_3)}{dt} &= 2\gamma_{5}I_{REC,0}(t,a,v_3) - 2\gamma_{5}I_{REC,1}(t,a,v_3) + 2\omega I_{REC,1}(t,a,v_2) - 2\psi I_{REC,1}(t,a,v_3) \\ \frac{dI_{RC,1}(t,a,v_3)}{dt} &= \gamma_{1}I_{MILD}(t,a,v_3) + 2\gamma_{3,1}I_{HOSPITAL,1}(t,a,v_3,0,1) + 2\gamma_{3,1}I_{HOSPITAL,1}(t,a,v_3,1,1) + 2\gamma_{5}I_{REC,1}(t,a,v_2) \\ &- 2\psi R_1(t,a,v_3) \\ \frac{dR_2(t,a,v_3)}{dt} &= 2\rho R_1(t,a,v_3) - 2\rho R_2(t,a,v_3) + 2\omega R_2(t,a,v_2) - 2\psi R_2(t,a,v_3) \\ \frac{dR_2(t,a,v_3)}{dt} &= 2\gamma_{4,1}I_{ROSPITAL,1}(t,a,v_3,0,0) + 2\gamma_{4,1}I_{ROSPITAL,1}(t,a,v_3,1,0) + 2\gamma_{4,0}I_{ROSPITAL,1}(t,a,v_3,0,0) \\ &+ 2\gamma_{4,0}I_{ROSPITAL,1}(t,a,v_3,0,0) + 2\gamma_{3,0}I_{HOSPITAL,1}(t,a,v_3,1,0) + 2\gamma_{4,0}I_{ROSPITAL,1}(t,a,v_3,1,0) \\ &+ 2\gamma_{4,0}I_{ROSPITAL,1}(t,a,v_3,1,0) \end{pmatrix}$$

# 1.3.5 Vaccination group v<sub>4</sub> - vaccinated and protected (state 2)

$$\begin{split} \frac{dS(t,a,v_4)}{dt} &= 2\rho R_2(t,a,v_4) - v_{lnf}(a)\beta \frac{S(t,a,v_4)}{N} \sum_{a} c(a,a') [\sum_{v} \left( l_{MILD}(t,a',v) + l_{CASE}(t,a',v) \right)] + 2\psi S(t,a,v_3) \\ &- 2\psi S(t,a,v_4) \\ \frac{dE_1(t,a,v_4)}{dt} &= v_{lnf}(a)\beta \frac{S(t,a,v_4)}{N} \sum_{a} c(a,a') [\sum_{v} (l_{MILD}(t,a',v) + l_{CASE}(t,a',v))] - 2aE_1(t,a,v_4) + 2\psi E_1(t,a,v_2) \\ - 2\psi E_1(t,a,v_4) &= 2aE_1(t,a,v_4) - 2aE_2(t,a,v_4) + 2\psi E_2(t,a,v_3) - 2\psi E_2(t,a,v_4) \\ \frac{dE_2(t,a,v_4)}{dt} &= (1 - v_{at_2}(a)\phi_1(a))(2aE_2(t,a,v_4)) - \gamma_1 l_{MILD}(t,a,v_4) + 2\psi l_{MILD}(t,a,v_3) - 2\psi l_{MILD}(t,a,v_4) \\ \frac{dC_{CASE}(t,a,v_4)}{dt} &= (1 - v_{at_2}(a)\phi_1(a))(2aE_2(t,a,v_4)) - \gamma_2 l_{CASE}(t,a,v_4) + 2\psi l_{CASE}(t,a,v_3) - 2\psi l_{MILD}(t,a,v_4) \\ \frac{dC_{CASE}(t,a,v_4)}{dt} &= 2\gamma_2 l_{CASE}(t,a,v_4) - 2\gamma_2 l_{CASE}(t,a,v_4) + 2\psi l_{CASE}(t,a,v_4) + 2\psi l_{CASE}(t,a,v_3) - 2\psi l_{CASE}(t,a,v_4) \\ \frac{dC_{CASE}(t,a,v_4)}{dt} &= 2\gamma_2 l_{CASE}(t,a,v_4) - 2\gamma_2 l_{CASE}(t,a,v_4) + 2\psi l_{CASE}(t,a,v_4) - 2\gamma_2 l_{CASE}(t,a,v_4) \\ \frac{dR_{IOSPITALD}(t,a,v_4,00)}{dt} &= (1 - \delta(H))\mu(a)(1 - \phi_2(a))2\gamma_2 l_{CASE}(t,a,v_4) - 2\gamma_3 l_{IOSPITAL}(t,a,v_4,0.0) \\ \frac{dR_{IOSPITAL}(t,a,v_4,0.0)}{dt} &= 2\gamma_3 a l_{IOSPITAL}(t,a,v_4,0.0) - 2\psi l_{HOSPITAL}(t,a,v_4,0.0) \\ \frac{dR_{IOSPITAL}(t,a,v_4,0.0)}{dt} &= 2\gamma_3 a l_{IOSPITAL}(t,a,v_4,0.0) - 2\gamma_3 a l_{IOSPITAL}(t,a,v_4,0.0) + 2\psi l_{IOSPITAL}(t,a,v_4,0.0) \\ \frac{dR_{IOSPITALD}(t,a,v_4,0.0)}{dt} &= 2\gamma_3 a l_{IOSPITAL}(t,a,v_4,0.0) - 2\gamma_3 a l_{IOSPITAL}(t,a,v_4,0.0) + 2\psi l_{IOSPITAL}(t,a,v_4,0.0) \\ \frac{dR_{IOSPITALD}(t,a,v_4,0.0)}{dt} &= 2\gamma_3 a l_{IOSPITALD}(t,a,v_4,0.0) - 2\gamma_3 a l_{IOSPITALD}(t,a,v_4,0.0) + 2\psi l_{IOSPITAL}(t,a,v_4,0.0) \\ \frac{dR_{IOSPITALD}(t,a,v_4,0.0)}{dt} &= 2\gamma_3 a l_{IOSPITALD}(t,a,v_4,0.0) - 2\gamma_3 a l_{IOSPITAL}(t,a,v_4,0.0) + 2\psi l_{IOSPITAL}(t,a,v_4,0.0) \\ \frac{dR_{IOSPITALD}(t,a,v_4,0.0)}{dt} &= 2\gamma_3 a l_{IOSPITALD}(t,a,v_4,0.1) - 2\gamma_3 a l_{IOSPITAL}(t,a,v_4,0.1) + 2\psi l_{IOSPITAL}(t,a,v_4,0.1) \\ \frac{dR_{IOSPITALD}(t,a,v_4,0.0)}{dt} &= 2\gamma_3 a l_{IOSPITALD}(t,a,v_4,0.1) - 2\gamma_3 a l_{IOSPITALD}(t,a,v_4,0.1) + 2\psi l_{IOSPITAL}(t,a,v_4,0.1) \\ \frac{dR_{IOSPITALD}$$

```
dI_{ICU,0}(t,\alpha,v_4,1,0)
                         dt
                                                         = \delta(ICU)\mu(a)\phi_2(a)2\gamma_2I_{CASE,1}(t,a,v_4) - 2\gamma_{4,0}I_{ICU,0}(t,a,v_4,1,0) + 2\psi I_{ICU,0}(t,a,v_3,1,0)
                                                         -2\psi I_{ICU,0}(t,a,v_4,1,0)
\frac{dI_{ICU,1}(t,a,v_4,1,0)}{dI_{ICU,0}(t,a,v_4,1,0)} = 2\gamma_{4,0}I_{ICU,0}(t,a,v_4,1,0) - 2\gamma_{4,0}I_{ICU,1}(t,a,v_4,1,0) + 2\psi I_{ICU,1}(t,a,v_3,1,0) - 2\psi I_{ICU,1}(t,a,v_4,1,0)
dI_{ICU,0}(t,\alpha,v_4,0,1)
                         dt
                                                         = (1 - \delta(ICU))(1 - \mu(a))\phi_2(a)2\gamma_2I_{CASE,1}(t, v_4, a) - 2\gamma_{4,1}I_{ICU,0}(t, a, v_4, 0, 1) + 2\psi I_{ICU,0}(t, a, v_3, 0, 1)
                                                         -2\psi I_{ICU.0}(t,a,v_4,0,1)
\frac{dI_{ICU,1}(t,a,v_4,0,1)}{dI_{ICU,1}(t,a,v_4,0,1)} = 2\gamma_{4,1}I_{ICU,0}(t,a,v_4,0,1) - 2\gamma_{4,1}I_{ICU,1}(t,a,v_4,0,1) + 2\psi I_{ICU,1}(t,a,v_3,0,1) - 2\psi I_{ICU,1}(t,a,v_4,0,1) + 2\psi I_{ICU,1}(t,a,v_4
dI_{ICU,0}(t,\alpha,v_4,1,1)
                         dt
                                                         = \delta(ICU)(1 - \mu(a))\phi_2(a)2\gamma_2I_{CASE,1}(t,a,v_4) - 2\gamma_{4,1}I_{ICU,0}(t,a,v_4,1,1) + 2\psi I_{ICU,0}(t,a,v_3,1,1)
                                                         -2\psi I_{ICU,0}(t,a,v_4,1,1)
\frac{dI_{ICU,1}(t,a,v_4,1,1)}{dt} = 2\gamma_{4,1}I_{ICU,0}(t,a,v_4,1,1) - 2\gamma_{4,1}I_{ICU,1}(t,a,v_4,1,1) + 2\psi I_{ICU,1}(t,a,v_3,1,1) - 2\psi I_{ICU,1}(t,a,v_4,1,1)
\frac{dI_{REC,0}(t,a,v_4)}{dt} = 2\gamma_{4,1}I_{ICU,1}(t,a,v_4,0,1) + 2\gamma_{4,1}I_{ICU,1}(t,a,v_4,1,1) - 2\gamma_5I_{REC,0}(t,a,v_4) + 2\psi I_{REC,0}(t,a,v_3)
                                                         -2\psi I_{REC.0}(t,a,v_4)
\frac{dI_{REC,1}(t,a,v_4)}{dt} = 2\gamma_5 I_{REC,0}(t,a,v_4) - 2\gamma_5 I_{REC,1}(t,a,v_4) + 2\psi I_{REC,1}(t,a,v_3) - 2\psi I_{REC,1}(t,a,v_4)
\frac{dR_{1}(t,a,v_{4})}{dt} = \gamma_{1}I_{MILD}(t,a,v_{4}) + 2\gamma_{3,1}I_{HOSPITAL,1}(t,a,v_{4},0,1) + 2\gamma_{3,1}I_{HOSPITAL,1}(t,a,v_{4},1,1) + 2\gamma_{5}I_{REC,1}(t,a,v_{4})
                                                         +2\gamma_{4,1}I_{ICU,1}(t,a,v_4,0,1)+2\gamma_{4,1}I_{ICU,1}(t,a,v_4,1,1)-2\rho R_1(t,a,v_4)+2\psi R_1(t,a,v_3)-2\psi R_1(t,a,v_4)
\frac{dR_2(t,a,v_4)}{dt} = 2\rho R_1(t,a,v_4) - 2\rho R_2(t,a,v_4) + 2\psi R_2(t,a,v_3) - 2\psi R_2(t,a,v_4)
\frac{dD(t, a, v_4)}{dt} = 2\gamma_{3,0}I_{HOSPITAL,1}(t, a, v_4, 0, 0) + 2\gamma_{3,0}I_{HOSPITAL,1}(t, a, v_4, 1, 0) + 2\gamma_{4,0}I_{ICU,1}(t, a, v_4, 0, 0)
                                                         +2\gamma_{4,0}I_{ICU,1}(t,a,v_4,1,0)
```

# 1.3.6 Vaccination group v<sub>5</sub> - previously vaccinated but no longer protected

$$\begin{split} \frac{dS(t,a,v_2)}{dt} &= 2\rho R_2(t,a,v_2) - \beta \frac{S(t,a,v_2)}{N} \sum_{\alpha} c(a,\alpha') \Big[ \sum_{t(Imin)} (t,a',v) + I_{CAST}(t,a',v) + 1 + 2\psi S(t,a,v_4) \\ \frac{dE_1(t,a,v_2)}{dt} &= \beta \frac{S(t,a,v_2)}{N} \sum_{\alpha} c(a,\alpha') \Big[ \sum_{t(Imin)} (t,a',v) + I_{CAST}(t,a',v) + 2\psi E_1(t,a,v_2) + 2\psi E_1(t,a,v_4) \\ \frac{dE_2(t,a,v_3)}{dt} &= 2\alpha E_1(t,a,v_3) - 2\alpha E_2(t,a,v_3) + 2\psi E_2(t,a,v_4) \\ \frac{dI_{MID}(t,a,v_3)}{dt} &= (1 - \phi_1(a))(2\alpha E_2(t,a,v_3)) - 2\gamma_2 I_{CASE_0}(t,a,v_3) + 2\psi I_{MID}(t,a,v_4) \\ \frac{dI_{MID}(t,a,v_3)}{dt} &= \phi_1(a)(2\alpha E_2(t,a,v_3)) - 2\gamma_2 I_{CASE_0}(t,a,v_3) + 2\psi I_{MID}(t,a,v_4) \\ \frac{dI_{CASE_0}(t,a,v_2)}{dt} &= 2\gamma_2 I_{CASE_0}(t,a,v_3) - 2\gamma_2 I_{CASE_0}(t,a,v_3) + 2\psi I_{CASE_1}(t,a,v_4) \\ \frac{dI_{CASE_0}(t,a,v_3)}{dt} &= 2\gamma_2 I_{CASE_0}(t,a,v_3) - 2\gamma_2 I_{CASE_0}(t,a,v_3) + 2\psi I_{CASE_1}(t,a,v_4) \\ \frac{dI_{CASE_0}(t,a,v_3)}{dt} &= (1 - \delta(H))\mu(a)(1 - \phi_2(a))2\gamma_2 I_{CASE_1}(t,a,v_3) - 2\gamma_3 I_{MOSPITAL_0}(t,a,v_5,0.0) \\ \frac{dI_{MOSPITAL_0}(t,a,v_5,0.0)}{dt} &= 2\gamma_3 I_{MOSPITAL_0}(t,a,v_5,0.0) - 2\gamma_3 I_{MOSPITAL_0}(t,a,v_5,0.0) + 2\psi I_{MOSPITAL_0}(t,a,v_4,0.0) \\ \frac{dI_{MOSPITAL_1}(t,a,v_5,0.0)}{dt} &= 2\gamma_3 I_{MOSPITAL_0}(t,a,v_5,1.0) - 2\gamma_3 I_{MOSPITAL_1}(t,a,v_5,1.0) + 2\psi I_{MOSPITAL_1}(t,a,v_5,0.0) \\ \frac{dI_{MOSPITAL_1}(t,a,v_5,0.0)}{dt} &= 2\gamma_3 I_{MOSPITAL_0}(t,a,v_5,0.0) - 2\gamma_3 I_{MOSPITAL_1}(t,a,v_5,1.0) + 2\psi I_{MOSPITAL_1}(t,a,v_5,0.1) \\ \frac{dI_{MOSPITAL_1}(t,a,v_5,0.1)}{dt} &= (1 - \delta(H))(1 - \mu(a))(1 - \phi_2(a))2\gamma_2 I_{CASE_1}(t,a,v_5) - 2\gamma_3 I_{MOSPITAL_1}(t,a,v_5,0.1) \\ \frac{dI_{MOSPITAL_1}(t,a,v_5,0.1)}{dt} &= 2\gamma_3 I_{MOSPITAL_0}(t,a,v_5,0.1) - 2\gamma_3 I_{MOSPITAL_1}(t,a,v_5,0.1) + 2\psi I_{MOSPITAL_1}(t,a,v_5,0.1) \\ \frac{dI_{MOSPITAL_1}(t,a,v_5,0.1)}{dt} &= 2\gamma_3 I_{MOSPITAL_0}(t,a,v_5,0.1) - 2\gamma_3 I_{MOSPITAL_1}(t,a,v_5,0.1) + 2\psi I_{MOSPITAL_1}(t,a,v_5,0.1) \\ \frac{dI_{MOSPITAL_1}(t,a,v_5,0.1)}{dt} &= (1 - \delta(HU))\mu(a)(1 - \phi_2(a))2\gamma_2 I_{CASE_1}(t,a,v_5) - 2\gamma_3 I_{MOSPITAL_1}(t,a,v_5,0.1) + 2\psi I_{MOSPITAL_1}(t,a,v_5,0.1) \\ \frac{dI_{MOSPITAL_1}(t,a,v_5,0.1)}{dt} &= 2\gamma_3 I_{MOSPITAL_0}(t,a,v_5,0.1) - 2\gamma_3 I_{MOSPITAL_1}(t,a,v_5,0.1) + 2\psi I_{MOSPITAL_1}(t,a,v_$$

$$\begin{split} \frac{dR_1(t,a,v_5)}{dt} &= \gamma_1 I_{MILD}(t,a,v_5) + 2\gamma_{3,1} I_{HOSPITAL,1}(t,a,v_5,0,1) + 2\gamma_{3,1} I_{HOSPITAL,1}(t,a,v_5,1,1) + 2\gamma_5 I_{REC,1}(t,a,v_5) \\ &\quad + 2\gamma_{4,1} I_{ICU,1}(t,a,v_5,0,1) + 2\gamma_{4,1} I_{ICU,1}(t,a,v_5,1,1) - 2\rho R_1(t,a,v_5) + 2\psi R_1(t,a,v_4) \\ \frac{dR_2(t,a,v_5)}{dt} &= 2\rho R_1(t,a,v_5) - 2\rho R_2(t,a,v_5) + 2\psi R_2(t,a,v_4) \\ \frac{dD(t,a,v_5)}{dt} &= 2\gamma_{3,0} I_{HOSPITAL,1}(t,a,v_5,0,0) + 2\gamma_{3,0} I_{HOSPITAL,1}(t,a,v_5,1,0) + 2\gamma_{4,0} I_{ICU,1}(t,a,v_5,0,0) \\ &\quad + 2\gamma_{4,0} I_{ICU,1}(t,a,v_5,1,0) \end{split}$$

#### 1.4 Model validation




Figure S2: Country-specific calibration of the SARS-CoV-2 transmission model (as at 18 January 2021)<sup>37</sup>. Four example countries are shown: Chad (low-income); Pakistan (lower-middle-income); Turkey (upper-middle-income); and Canada (high-income). Each upper panel shows the modelled daily deaths calibrated to the daily deaths as reported by the COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University<sup>38</sup>. For countries not included in that repository, data are obtained from Worldometer<sup>39</sup>. Each middle panel shows the daily number of infections estimated by fitting to the current total of deaths, with reported cases shown in red and the model-estimated infections shown in blue (dark blue 50% interquartile range, light blue 95% quantile). The dashed vertical lines show the current day. Each lower panel shows the estimated reproduction number over time, R<sub>t</sub>.

# 1.5 Timing of transmission and vaccination





Figure S3: Schematic illustration of the timing of changes in levels of transmission and the introduction of vaccination.

# 1.6 Additional methods for vaccine age-targeting

For the global optimisation of vaccine allocation by income setting and age target, we run the simulation for the vaccine distributed to combinations of 5-year age groups from 0–4 years up to 75–79 years and 80+ years. Rather than simulating impact for every possible combination of age groups targeted, we construct the parameter space such that the vaccine could be targeted to up to two distinct contiguous groups, or rather up two non-overlapping age groups that are each comprised of any number of consecutive 5-year groups. The age group combinations are depicted in Figure S4.



**Figure S4: Illustration of 5-year age group combinations.** Each column represents a unique vaccine agetargeting strategy indicating which age groups (rows) are vaccinated (grey shaded regions) or unvaccinated (unshaded regions) for that strategy.

# 2 Extended results




Figure S5: Scenarios for the course of the epidemic from 2020–2022, for high-income, upper-middle-income, lower-middle-income and low-income country settings (HIC, UMIC, LMIC and LIC respectively). (A, C, E, G) assuming an average duration of naturally acquired immunity of one year; (B, D, F, H) assuming long-term immunity. We assume  $R_0$ =2.5 up to time  $t_1$  (May 2020) and that  $R_{t1}$  drops to 1.1 between time  $t_1$  and  $t_2$  (end-February 2021). From time  $t_2$  onwards, we consider three counterfactual scenarios,  $R_{t2}$ =1.5, 2.0 and 2.5, as shown in light green, purple and turquoise respectively. The grey annotated text indicates the proportion of the population in the recovered class at the time of vaccine introduction (dose 2).




Figure S6: Scenarios for the course of the epidemic from 2020–2022 (counterfactual scenarios). Epidemic trajectories are shown for a high-income country setting, in the absence of a vaccine, for a range of values of  $R_0$  (rows),  $R_{t1}$  (columns), and  $R_{t2}$  (coloured lines). The grey annotated text indicates the proportion of the population in the recovered class at the time of vaccine introduction (dose 2). Immunity following infection is assumed to persist for one year.




Figure S7: Vaccine efficacy and herd immunity by income setting. Projected total deaths averted per thousand population in 2021 under the default vaccine scenarios shown in Table 1, for the four income settings (columns), and with health system constraints either absent or present (rows). The colours show different vaccine efficacy assumptions (from 50% to 90%). Solid lines represent impact for a vaccine that is efficacious against infection, with additional efficacy against severe disease. Dashed lines represent a vaccine that is efficacious against infection only, and dotted lines represent a vaccine that prevents severe disease (and hence death) but does not reduce infection or onwards transmission (Table S3).




Figure S8: Epidemic trajectories and impact of immunity. Epidemic scenarios are shown for the period 2020–2022, both in the absence of a vaccine (dashed black lines) and following vaccine introduction (solid black lines). Vaccine implementation is indicated by the red and blue vertical lines. The left panel represents the scenario where vaccine-derived immunity is long-term, and naturally derived immunity is one year. The middle panel represents where both vaccine- and naturally derived immunity are one year, while the right panel shows trajectories where both durations are six months. Trajectories are shown for a high-income country setting, and assuming the default transmission and vaccine parameters as in Table 1.





Figure S9: Vaccine impact over a one-year vaccination period. Here, NPIs are assumed to be lifted when the vaccine is introduced, rather than after the target population is vaccinated, and the target population is vaccinated over a period of one year. Vaccination start is shown by the vertical dashed line, and vaccination stop by the vertical dotted line. Three different values of  $R_{t2}$  are shown:  $R_{t2} = 1.5$  (A,B);  $R_{t2} = 2.0$  (C,D; the default value) and  $R_{t2} = 2.5$  (E,F). The left-hand-side panels show the deaths per million per day, for the counterfactual scenario (long-dashed black line), and three vaccine targeting strategies (coloured lined). The right-hand-side panels show the total deaths averted in 2021–2022 per thousand population for three vaccine targeting strategies, where vaccination takes place at a constant rate over the course of 2021. "All": all age groups vaccinated simultaneously. "Target older": the 80+ group is vaccinated first, then additional groups (75–79, 70–74 and so on) are consecutively vaccinated. "Target working-age": the 15–64-year-old group is vaccinated first, and then the older group, and then children.



**Figure S10: Resources required when vaccine introduction is targeted by age.** Here, the highest risk age groups are prioritised. Resources required is presented as a proportion of the total population.




Figure S11: Efficiency frontier for the age targeting of a vaccine within each income setting. The black circles each represent a unique age targeting strategy, for each income setting, for increasing availability of doses on the x-axis, versus impact in terms of deaths averted per thousand population on the y-axis. The red points represent the most efficient (non-dominated) age-targeting strategies, or the maximum deaths averted as the vaccine supply is increased. These red points correspond to the age targeting strategies shown in Figure 4A, C, E and G, and the optimal allocation strategy in Figure 4B, D, F and H.




Figure S12: Sensitivity analysis of targeting of vaccine introduction within each income setting; lower vaccine efficacy (70%). These panels illustrate the most efficient allocation under different dose constraints, where the supply is defined as the proportion of the population able to access two doses. Panels A, C, E and G show the age groups allocated under each supply level, where the purple shaded regions indicate the age groups allocated the vaccine. Panels B, D, F and H show the efficiency frontiers expressed as deaths averted per thousand population as a function of vaccine supply. The optimal strategies from the left-hand panels are shown in purple. The turquoise shows the strategy that prioritises the older at-risk age: 80+ for the lowest coverage level, and sequentially including additional age groups (75–79, 70–74 and so on) as additional doses are available. The green strategy prioritises the working age population first (beginning with the 60–64 age group and sequentially adding younger groups), then vaccinates the elderly and children as doses become available.




Figure S13: Sensitivity analysis of targeting of vaccine introduction within each income setting; reduced vaccine impact in 65+ age group (immunosenescence). Vaccine efficacy was reduced in the 65+ age group to 35%. These panels illustrate the most efficient allocation under different dose constraints, where the supply is defined as the proportion of the population able to access two doses. Panels A, C, E and G show the age groups allocated under each supply level, where the purple shaded regions indicate the age groups allocated the vaccine. Panels B, D, F and H show the efficiency frontiers expressed as deaths averted per thousand population as a function of vaccine supply. The optimal strategies from the left-hand panels are shown in purple. The turquoise shows the strategy that prioritises the older at-risk age: 80+ for the lowest coverage level, and sequentially including additional age groups (75–79, 70–74 and so on) as additional doses are available. The green strategy prioritises the working age population first (beginning with the 60–64 age group and sequentially adding younger groups), then vaccinates the elderly and children as doses become available.




Figure S14: Sensitivity analysis of targeting of vaccine introduction within each income setting; vaccine efficacious against disease only. These panels illustrate the most efficient allocation under different dose constraints, where the supply is defined as the proportion of the population able to access two doses. Panels A, C, E and G show the age groups allocated under each supply level, where the purple shaded regions indicate the age groups allocated the vaccine. Panels B, D, F and H show the efficiency frontiers expressed as deaths averted per thousand population as a function of vaccine supply. The optimal strategies from the left-hand panels are shown in purple. The turquoise shows the strategy that prioritises the older at-risk age: 80+ for the lowest coverage level, and sequentially including additional age groups (75–79, 70–74 and so on) as additional doses are available. The green strategy prioritises the working age population first (beginning with the 60–64 age group and sequentially adding younger groups), then vaccinates the elderly and children as doses become available.




Figure S15: Sensitivity analysis of targeting of vaccine introduction within each income setting; R<sub>t2</sub>=1.5. These panels illustrate the most efficient allocation under different dose constraints, where the supply is defined as the proportion of the population able to access two doses. Panels A, C, E and G show the age groups allocated under each supply level, where the purple shaded regions indicate the age groups allocated the vaccine. Panels B, D, F and H show the efficiency frontiers expressed as deaths averted per thousand population as a function of vaccine supply. The optimal strategies from the left-hand panels are shown in purple. The turquoise shows the strategy that prioritises the older at-risk age: 80+ for the lowest coverage level, and sequentially including additional age groups (75–79, 70–74 and so on) as additional doses are available. The green strategy prioritises the working age population first (beginning with the 60–64 age group and sequentially adding younger groups), then vaccinates the elderly and children as doses become available.




Figure S16: Sensitivity analysis of targeting of vaccine introduction within each income setting;  $R_{t2}$ =2.5. These panels illustrate the most efficient allocation under different dose constraints, where the supply is defined as the proportion of the population able to access two doses. Panels A, C, E and G show the age groups allocated under each supply level, where the purple shaded regions indicate the age groups allocated the vaccine. Panels B, D, F and H show the efficiency frontiers expressed as deaths averted per thousand population as a function of vaccine supply. The optimal strategies from the left-hand panels are shown in purple. The turquoise shows the strategy that prioritises the older at-risk age: 80+ for the lowest coverage level, and sequentially including additional age groups (75–79, 70–74 and so on) as additional doses are available. The green strategy prioritises the working age population first (beginning with the 60–64 age group and sequentially adding younger groups), then vaccinates the elderly and children as doses become available.




Figure S17: Sensitivity analysis of targeting of vaccine introduction within each income setting; health system constraints absent. These panels illustrate the most efficient allocation under different dose constraints, where the supply is defined as the proportion of the population able to access two doses. Panels A, C, E and G show the age groups allocated under each supply level, where the purple shaded regions indicate the age groups allocated the vaccine. Panels B, D, F and H show the efficiency frontiers expressed as deaths averted per thousand population as a function of vaccine supply. The optimal strategies from the left-hand panels are shown in purple. The turquoise shows the strategy that prioritises the older at-risk age: 80+ for the lowest coverage level, and sequentially including additional age groups (75–79, 70–74 and so on) as additional doses are available. The green strategy prioritises the working age population first (beginning with the 60–64 age group and sequentially adding younger groups), then vaccinates the elderly and children as doses become available.




Figure S18: Sensitivity analysis of targeting of vaccine introduction within each income setting; transmission from children younger than 10 years reduced by 50%. These panels illustrate the most efficient allocation under different dose constraints, where the supply is defined as the proportion of the population able to access two doses. Panels A, C, E and G show the age groups allocated under each supply level, where the purple shaded regions indicate the age groups allocated the vaccine. Panels B, D, F and H show the efficiency frontiers expressed as deaths averted per thousand population as a function of vaccine supply. The optimal strategies from the left-hand panels are shown in purple. The turquoise shows the strategy that prioritises the older at-risk age: 80+ for the lowest coverage level, and sequentially including additional age groups (75–79, 70–74 and so on) as additional doses are available. The green strategy prioritises the working age population first (beginning with the 60–64 age group and sequentially adding younger groups), then vaccinates the elderly and children as doses become available.




Figure S19: Sensitivity analysis of targeting of vaccine introduction within each income setting; life-years gained as outcome measure. These panels illustrate the most efficient allocation under different dose constraints, where the supply is defined as the proportion of the population able to access two doses. Panels A, C, E and G show the age groups allocated under each supply level, where the purple shaded regions indicate the age groups allocated the vaccine. Panels B, D, F and H show the efficiency frontiers expressed as life-years gained per thousand population as a function of vaccine supply. The optimal strategies from the left-hand panels are shown in purple. The turquoise shows the strategy that prioritises the older at-risk age: 80+ for the lowest coverage level, and sequentially including additional age groups (75–79, 70–74 and so on) as additional doses are available. The green strategy prioritises the working age population first (beginning with the 60–64 age group and sequentially adding younger groups), then vaccinates the elderly and children as doses become available.




Figure S20: Vaccine impact by income setting and level of NPIs at vaccine introduction. Deaths averted (A, C, E) and life years gained (B, D, F) per thousand population in 2021 for each income setting (x-axis), where health systems are either unconstrained (dark grey) or constrained (light grey), and for  $R_{t2} = 2.5$  (upper row),  $R_{t2}=2$  (default value, middle row) and  $R_{t2}=1.5$  (lower row). Default vaccine parameters are in Table 1.

**Table S4: Global allocation of vaccine doses for non-optimised scenarios**. Here we assume that limited countries within each income setting are allocated doses at high (80%) coverage, rather than all countries being allocated doses at a lower level of coverage as in Table 2. The global vaccine supply is assumed to be constrained to 2 billion doses, with a two-dose schedule and 15% buffer and wastage (resulting in 0.85 billion vaccine courses available). FVP: fully vaccinated persons.

Allocations	strategy	Income setting	Target age group	Deaths averted per million	Deaths averted per 100 FVP	Total deaths averted per million global population	Total deaths averted per 100 FVP
		HIC	all	450	0.4		
	A: Countries receive doses	UMIC	all	300	0.27	348	0.31
	in proportion to population	LMIC	all	346	0.31	346	
		LIC	all	378	0.34		
	B: Countries receive doses	HIC	15+	1293	1.16		
	in proportion to population, with 65+ group prioritised	UMIC	15+	1268	1.14		1.18
	and remaining doses	LMIC	15+	1388	1.25	1316	
	allocated to 15-64 age groups	LIC	15+	1238	1.11		
	C: Countries receive doses	HIC	15+	2260	0.9		1.25
	in proportion to 65+ population, with 65+ group prioritised and remaining doses allocated to 15-64 age groups	UMIC	15+	1252	1.09	1394	
Allocated		LMIC	15+	1279	1.91		
to limited countries		LIC	15+	932	2.56		
at 80%	D: Allocated first to high- income countries	HIC	all	2837	0.4		0.40
coverage		UMIC	all	0	0	450	
		LMIC	all	0	0	450	
		LIC	all	0	0		
	E: Allocated first to low- income and lower-middle- income countries	HIC	all	0	0		0.32
		UMIC	all	0	0	352	
-		LMIC	all	740	0.31	352	
		LIC	all	808	0.34		
	F: Countries receive doses in proportion to population,	HIC	all	2081	0.4		0.33
		UMIC	all	519	0.27	785	
	plus 1.15 b doses to HIC	LMIC	all	598	0.31	/85	
	and 1.1 b doses to MIC	LIC	all	378	0.34		

Table S5: Optimised global allocation of vaccine doses for different assumptions about vaccine characteristics, transmission, health system constraints, and optimisation outcome.

Parameter assumption	Income setting	Deaths averted per million	Deaths averted per 100 fully vaccinated persons	Total deaths averted per million global population	Total deaths averted per 100 fully vaccinated persons	
	HIC	3135	1.16			
Defect	UMIC	1241	1.44	1672	1 42	
Default	LMIC	1581	1.62	1672	1.43	
	LIC	1533	1.81			
	HIC	3068	0.94			
Lower vaccine efficacy	UMIC	1073	1.37	1407	1.20	
(70%)	LMIC	1365	1.61	1497	1.28	
	LIC	1335	1.58			
	HIC	3135	1.16			
Reduced vaccine efficacy	UMIC	1235	1.07	4500	1.20	
(scaled by 50%) in 65+ years population	LMIC	1202	1.73	1503	1.28	
years population	LIC	1330	1.57			
	HIC	1773	0.97			
Vaccine efficacious against	UMIC	1068	1.36			
disease only	LMIC	1544	1.18	1391	1.19	
	LIC	1483	1.28			
NPIs maintained at higher	HIC	1551	1.37	1259	1.07	
level following vaccine	UMIC	1131	0.99			
introduction (such that	LMIC	1145	1.02			
R <sub>t2</sub> =1.5)	LIC	1856	1.19			
NPIs maintained at lower	HIC	3734	1.28			
level following vaccine	UMIC	1573	2.01			
introduction (such that	LMIC	2698	2.76	2331	1.99	
R <sub>t2</sub> =2.5)	LIC	1659	1.96			
	HIC	3135	1.16			
Health system constraints	UMIC	1602	1.06			
absent	LMIC	790	1.74	1417	1.21	
	LIC	585	1.46			
	HIC	3381	1.16			
Reduced infectiousness in	UMIC	1238	1.58			
children younger than 10 years	LMIC	1639	1.68	1730	1.48	
	LIC	1549	1.83			
Life-years gained as optimisation outcome	HIC	3135	1.16			
	UMIC	593	3.52	_		
	LMIC	1612	1.51	1532	1.31	
measure	LIC	2614	0.75			

Table S6: Sensitivity analysis for the fixed global vaccine allocation scenarios.

		Sensitivity Analysis							
		Total deaths averted per million global population							
		(Total deaths averted per 100 fully vaccinated people)							
					NPIs maintained	NPIs maintained			
		Lower vaccine efficacy (70%)			at higher level	at lower level			
			Reduced		following	following		Reduced	
	Default		vaccine efficacy	Vaccine	vaccine	vaccine		infectiousness	
			(scaled by 50%)	efficacious	introduction	introduction	Health system	in children	
			in 65+ years	against disease	(such that	(such that	constraints	younger than 10	
			population	only	R <sub>t2</sub> =1.5)	R <sub>t2</sub> =2.5)	absent	years	
A: Countries receive doses in	650 (0.59)	524 (0.48)	609 (0.55)	289 (0.26)	562 (0.51)	809 (0.74)	484 (0.44)	671 (0.61)	
proportion to population	030 (0.33)	324 (0.48)	009 (0.55)	289 (0.20)	302 (0.31)	803 (0.74)	484 (0.44)	071 (0.01)	
B: Countries receive doses in									
proportion to population,	1324 (1.2)	1182 (1.07)	1082 (0.98)	1118 (1.01)	756 (0.68)	1936 (1.75)	1091 (0.99)	1393 (1.26)	
targeted first to 65+, then 15-64	1324 (1.2)	1102 (1.07)	1002 (0.50)	1110 (1.01)	750 (0.00)	1550 (1.75)	1031 (0.33)	1333 (1.20)	
age groups									
C: Countries receive doses in									
proportion to population in 65+	1386 (1.25)	1245 (1.12)	1135 (1.02)	1188 (1.07)	767 (0.69)	1995 (1.8)	1193 (1.07)	1461 (1.32)	
age group, targeted first to 65+,	1300 (1.23)	1243 (1.12)	1133 (1.02)	1100 (1.07)	707 (0.03)	1333 (1.0)	1133 (1.07)	1401 (1.32)	
then 15-64 age groups									
D: Allocated first to high-income	513 (0.46)	513 (0.46)	513 (0.46)	330 (0.3)	264 (0.24)	713 (0.64)	513 (0.46)	559 (0.5)	
countries	313 (0.40)	313 (0.40)	313 (0.40)	330 (0.3)	204 (0.24)	713 (0.04)	313 (0.40)	333 (0.3)	
E: Allocated first to low-income									
and lower-middle-income	597 (0.53)	484 (0.43)	571 (0.51)	319 (0.28)	635 (0.57)	908 (0.81)	331 (0.29)	610 (0.54)	
countries									
F: Countries receive doses in		08 (0.56) 1103 (0.47)	1266 (0.54)	625 (0.27)	1075 (0.46)	1710 (0.73)	1098 (0.47)	1374 (0.59)	
proportion to population, plus	1308 (0.56)								
additional 1.15 b doses to HIC and	1300 (0.30)		1200 (0.54)	023 (0.27)	10/3 (0.40)	1710 (0.73)	1030 (0.47)	1377 (0.33)	
1.1 b doses to MIC									

#### 3 References

- 1 Walker PGT, Whittaker C, Watson OJ, *et al.* The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. *Science* (80-) 2020; **422**: eabc0035.
- Pritchard M, Dankwa EA, Hall M, et al. ISARIC Clinical Data Report 4 October 2020. medRxiv 2020. DOI:https://doi.org/10.1101/2020.07.17.20155218.
- 3 (ICNARC) ICNA& RC. ICNARC report on COVID-19 in critical care 16 October 2020. 2020. https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports.
- 4 Brazeau NF, Verity R, Jenks S, *et al.* Report 34 COVID-19 Infection Fatality Ratio estimates from seroprevalence. 2020. DOI:https://doi.org/10.25561/83545.
- Linton NM, Kobayashi T, Yang Y, *et al.* Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. *J Clin Med* 2020; **9**: 538.
- 6 Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *N Engl J Med* 2020; **382**: 1199–207.
- Lauer SA, Grantz KH, Bi Q, *et al.* The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med* 2020; **172**: 577–82.
- Bi Q, Wu Y, Mei S, *et al.* Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* 2020; **20**: 911–9.
- Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ 2020; **369**: 1–12.
- Hawryluk I, Mellan TA, Hoeltgebaum HH, et al. Inference of COVID-19 epidemiological distributions from Brazilian hospital data. *J R Soc Interface* 2020; **17**: 20200596.
- South African COVID-19 Modelling Consortium X. Estimating cases for COVID-19 in South Africa. Short term Projections June 2020. 2020 https://www.nicd.ac.za/wp-content/uploads/2020/06/SACovidModellingReport\_ShortTermProjections\_12062020\_Final2.pdf.
- Sreevalsan-Nair J, Vangimalla RR, Ghogale PR. Analysis and estimation of length of in-hospital stay using demographic data of COVID-19 recovered patients in Singapore. *medRxiv* 2020. DOI:https://doi.org/10.1101/2020.04.17.20069724.
- Haw NJL, Uy J, Sy KTL, Abrigo MRM. Epidemiological profile and transmission dynamics of COVID-19 in the Philippines. *Epidemiol Infect* 2020; **148**: e204.
- Oliveira E, Parikh A, Lopez-Ruiz A, *et al.* ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in Central Florida. *medRxiv* 2020. DOI:https://doi.org/10.1101/2020.08.25.20181909.
- Salje H, Kiem CT, Lefrancq N, et al. Estimating the burden of SARS-CoV-2 in France. Science (80- ) 2020; **369**: 208–11.
- To KKW, Hung IF, Ip JD, *et al.* COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. *Clin Infect Dis* 2020; : ciaa1275.
- 17 Ministerio de Ciencia e Innovaciaon Gobierno de Espana, Ministerio de Sanidad Gobierno de Espana, Consejo Interterritorial, Instituto de Salud Carlos III. Estudio Nacional de Sero-Epidemiolgia de la Infeccion por SARS-CoV-2 en Espana: Informe Final. 2020 https://www.mscbs.gob.es/ciudadanos/enecovid/.
- Hall V, Foulkes S, Charlett A, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. medRxiv 2021; : 2021.01.13.21249642.

- Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Articles Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020 : a population-level observational study. *Lancet* 2021; **6736**: 1–9.
- Dan JM, Mateus J, Kato Y, *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* (80-) 2021; **371**. DOI:10.1126/science.abf4063.
- L.A. Jackson, E.J. Anderson, N.G. Rouphael, P.C. Roberts, M. Makhene, R.N. Coler, M.P. McCullough, J.D. Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A. McDermott, B. Flach, N.A. Doria-Rose KSC, K.M. Morabito, S. O'Dell, S.D. Schmidt, P.A. Swanson II, M. Padilla, J.R. Mascola, K.M. Neuzil, H. Bennett, W. Sun, E. Peters, M. Makowski, J. Albert KC, W. Buchanan, R. Pikaart-Tautges, J.E. Ledgerwood, B.S. Graham, and J.H. Beigel for the mRNA-1273 SG. An mRNA Vaccine against SARS-CoV-2 Preliminary Report. N Engl J Med 2020; 383: 1920–31.
- Folegatti PM, Ewer KJ, Aley PK, et al. Articles Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1 / 2, single-blind, randomised controlled trial. Lancet 2020; **396**: 467–78.
- Zhu FC, Li YH, Guan XH, *et al.* Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *Lancet* 2020; **395**: 1845–54.
- Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020; **586**: 589–93.
- Sahin U, Muik A, Derhovanessian E, *et al.* COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature* 2020; **586**: 594–9.
- World Health Organization. WHO Target Product Profiles for COVID-19 Vaccines. Version 3. Geneva, 2020 https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines.
- Voysey M, Clemens SAC, Madhi SA, *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2020; **397**: 99–111.
- Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* 2021; **19**: 881–91.
- Weekes M, Jones NK, Rivett L, et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. *Authorea* 2021. DOI:10.22541/au.161420511.12987747/v1.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; **383**: 2603–15.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2020; **384**: 403–16.
- Logunov DY, Dolzhikova I V, Shcheblyakov D V, *et al.* Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* 2021; **397**: 671–81.
- Public Health England. PHE monitoring of the early impact and effectiveness of COVID-19 vaccination in England, 22 February 2021. 2021; : 1–17.
- Bernal JL, Andrews N, Gower C, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv 2021.
- Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. *Lancet* 2021; **397**: 875–7.
- 36 Hall V, Foulkes S, Saei A, et al. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-

- 19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). SSRN Prepr 2021. https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=3790399.
- 37 MRC Centre for Global Infectious Disease Analysis Imperial College London. Future scenarios of the healthcare burden of COVID-19 in Low- or Middle-income countries. 2021. https://mrc-ide.github.io/global-lmic-reports/ (accessed Jan 26, 2021).
- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* 2020; **20**: 533–4.
- Worldometer. Coronavirus updates. https://www.worldometers.info/ (accessed Jan 26, 2021).